56 filings
8-K
SLDB
Solid Biosciences Inc
8 Jan 24
Entry into a Material Definitive Agreement
7:24am
8-K
SLDB
Solid Biosciences Inc
15 Nov 23
Solid Biosciences Announces IND Clearance by FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003
7:59am
8-K
SLDB
Solid Biosciences Inc
9 Jun 23
Departure of Directors or Certain Officers
4:30pm
8-K
SLDB
Solid Biosciences Inc
22 May 23
Departure of Directors or Certain Officers
4:31pm
8-K
SLDB
Solid Biosciences Inc
20 Mar 23
Regulation FD Disclosure
7:30am
8-K
ig2zl9tds5wf
13 Mar 23
Regulation FD Disclosure
7:30am
8-K
z95kl
9 Jan 23
Results of Operations and Financial Condition
8:09am
8-K
un9l4l0rcorqotji17g
5 Dec 22
Solid Biosciences Announces Closing of Acquisition of AavantiBio and Concurrent $75 Million Private Placement
7:48am
8-K
lbmcct dg
1 Dec 22
Departure of Directors or Certain Officers
4:34pm
8-K
t2xow54r7rup92ptc8
27 Oct 22
Material Modifications to Rights of Security Holders
5:16pm
8-K
9jek3h x5ak
30 Sep 22
Business Update Call
4:07pm
8-K
zqffhxndtlnyyrpph
30 Sep 22
Solid Biosciences Announces Acquisition of AavantiBio and Concurrent $75 Million Private Placement
7:09am
8-K
ccps15
11 Aug 22
Solid Biosciences Provides Second Quarter 2022 Business Update and Financial Results
8:04am
8-K
7l89v 3n0pa2dsjx2
9 Jun 22
Submission of Matters to a Vote of Security Holders
4:30pm
8-K
dh093f3a67i0n3 ea
6 Jun 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:11pm
8-K
9qe208 o3u8
27 Apr 22
Solid Biosciences Announces Updated Corporate Strategy to Develop SGT-001 and SGT-003 Pipeline Programs for Patients with Duchenne Muscular Dystrophy
7:43am
8-K
zdyhzqy
4 Apr 22
Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics
4:09pm
8-K
ay1c2 nzx
10 Jan 22
Solid Biosciences Outlines its Strategic Priorities for 2022 and Announces Corporate Updates
8:10am
8-K
pd2w6o3gc54mx2oia
29 Sep 21
Other Events
7:25am
8-K/A
g52cboyns x9frataj
27 Sep 21
Other Events
7:33am